{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 37,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/22",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.198,
        "w": 0.882,
        "x": 0.059,
        "y": 0.686
      },
      "kind": "list",
      "text": "Corporate: Workforce reduction announced in April 2023; Exploring strategic alternatives; Estimated $39.8 million in cash and cash equivalents as of March 31, 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b811d4e-2c82-44e7-8d38-a960dbe75b74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.135,
        "w": 0.882,
        "x": 0.059,
        "y": 0.448
      },
      "kind": "list",
      "text": "Pegzilarginase in Arginase 1 Deficiency: MAA under review with EMA, potential decision on approval in late 2023; Partnered in Europe and certain countries in Middle East",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0c93424-e076-4182-98ed-3cd3e0d2f3f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.198,
        "w": 0.882,
        "x": 0.059,
        "y": 0.182
      },
      "kind": "list",
      "text": "Pegtarviliase in Homocystinuria: Announced interim results from Cohorts 1-3 in April 2023; Data from Cohorts 1 and 2 suggested a dose-dependent treatment effect; Cohort 3 data confounded by presence of anti-drug antibodies (ADAs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c470373b-16b9-45c0-9cd9-c2f3bfa4b510",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.565,
        "x": 0.182,
        "y": 0.939
      },
      "kind": "source-note",
      "text": "1 Because our condensed consolidated financial statements for the quarter ended March 31, 2023 have not been finalized, this preliminary estimate of cash and cash equivalents... may differ materially from this preliminary estimate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cb00fc2-c56b-4572-973a-58fcdc547abb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.662,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Recent Developments and Upcoming Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2157a9b-c7d7-41b3-b807-1ebe4cc3b475",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}